This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are at an increased risk of deaths (all-cause). Clinical malaria, severe malaria and death (all-cause) cases will be enrolled in study. For each case (severe or death) 4 controls matched for age and neighborhood will be enrolled whereas for clinical malaria case, 1 matched control will be enrolled. 1. Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum. 2. Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases in high-transmission perennial areas caused by P. falciparum. 3. Proportion of vaccinated and unvaccinated children in cases of death (all cause) 4. Exploratory effectiveness endpoint: Proportion of vaccinated and unvaccinated children in the hospitalized clinical and severe malaria cases.
The study will be conducted at multiple centers with the appropriate research infrastructure to carry out safety and/or effectiveness research across different countries where the R21/Matrix-M vaccine is (or will be) approved and deployed for vaccination with subsequent population uptake. The cases will be enrolled from hospitals/clinics and the matched controls will be recruited from the community by visiting the neighborhood. Children eligible for receiving R21/Matrix-M vaccine, residing in the geographical area where the vaccine has been deployed will be considered as either cases or controls if they meet the eligibility criteria. All participants will be screened for eligibility after obtaining informed written consent from parents/legal guardians/ caregivers. Surveillance and detection of cases: Cases qualifying the case definitions of clinical or severe malaria, cases will be recruited from the hospitals, clinics or the sub-sites. For deaths, cases will be recruited from the hospital or the community. Cause of death will be ascertained from hospital or available medical records as well as discussions with family or healthcare professionals who may have been involved. Identification of controls: Four controls for each case will be recruited by study physician or field staff from community for severe malaria and death cases. For clinical malaria cases in high-transmission perennial areas, case: control ratio will be 1:1. Controls will be matched for age and neighborhood. Controls should be residing in the same neighborhood as the respective case, but not from the same house. Living controls will be enrolled against the death cases. Vaccination status will be confirmed from the vaccination/immunization cards, hospital/clinic records, home based registers, or national immunization database. History from the parents/ guardians/ caregivers will be considered in case of non-vaccination. Field staff may visit the homes of controls and (if required) cases for collection of the required data.
Study Type
OBSERVATIONAL
Enrollment
2,308
Case control study of clinical malaria
Case control study of severe malaria
Case control study of death (all cause)
Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest (IRSS-DRCO), Bousse
Boussé, Burkina Faso, Burkina Faso
RECRUITINGCentre de Recherche et de Lutte contre le Paludisme Institut National de Santé Publique, boulevard Nangui Abrogoua près État Major des Armées
Toumodi, Côte d’Ivoire
RECRUITINGUniversity of Ilorin Department of Pediatrics University of Ilorin Teaching Hospital, Ilorin, Nigeria
Yenagoa, Bayesla, Nigeria
RECRUITINGInfectious Diseases Research Collaboration (IDRC), Uganda
Busia, Uganda, Uganda
RECRUITINGMakerere University College of Health Sciences
Mukono, Uganda
RECRUITINGVaccine Effectiveness against Severe Malaria caused by P. falciparum
Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum.
Time frame: through study, an average of one year
Vaccine Effectiveness against clinical malaria caused by P. falciparum in high perennial transmission areas
Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases caused by P. falciparum.
Time frame: through study, an average of one year
Risk of death (all cause) due to R21-vaccination
Proportion of vaccinated and unvaccinated children in cases of death
Time frame: through study, an average of one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.